Abstract Background Immune checkpoint inhibitors (ICIs) can cause serious immune-related
adverse events (irAEs). This study aimed to identify risk factors for all types of irAEs induced …

Abstract Background Immune checkpoint inhibitors (ICIs) have significant clinical efficacy in
the treatment of non‐small cell lung cancer (NSCLC); however, the incidence of immune …

Abstract Background Immune checkpoint inhibitors (ICIs) are available for first-and further
lines of treatment of patients with advanced non–small-cell lung cancer (NSCLC). These …

Patients treated with immune checkpoint inhibitors (ICIs) often experience unique immune-
related adverse events (irAEs), and the previous studies demonstrated an association …

Background Immune-related adverse events (irAEs) have been reported to be associated
with the efficacy of immunotherapy. Herein, we conducted a meta-analysis to demonstrate …

Objective A complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint
inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC) will be …

Abstract Background: Immune checkpoint inhibitors (ICIs) emerged as the preferred therapy
in advanced lung cancer, understanding the treatment-and immune-related adverse events …

Immune‐related adverse events (IrAEs) of immune checkpoint inhibitors (ICIs) can be
serious and unpredictable. We examine the incidence rate and risk factors for IrAEs in an …

Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile,
and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non …

Background: The impact of immune-related adverse events (irAE) on survival outcomes after
single-agent immune checkpoint inhibitors (ICIs) remains unclear. We aimed to evaluate the …